Procter & Gamble Health Limited announced today its financial results for the quarter ended March 31, 2021. The company has recorded sales of ₹ 214 crores down by 4% vs corresponding quarter of last year, impacted by stock challenges and higher last year base on account of exports sales phasing during the same quarter last year. Sales for nine months ending March 31, 2021 are ₹ 710 Crores, up by 5% vs nine months year ago. The Profit After Tax (PAT) is ₹ 15.8 crores vs ₹ 46.5 crores in the corresponding quarter last year, impacted by lower sales for the quarter and lower expense base last year supported by provision true-ups and reversals. PAT for nine months ended March 31, 2021 is ₹ 142.9 crores vs ₹ 120.4 crores, up by 19% vs nine months period of last year.
Milind Thatte, Managing Director, Procter & Gamble Health Limited said, “As the country and the entire healthcare ecosystem is faced with one of the most challenging circumstances in recent times, Procter & Gamble Health Limited stands committed to working with healthcare practitioners and distribution partners towards ensuring uninterrupted service and supplies of our medicines and nutraceutical products to patients and consumers across India. Amidst turbulent times, the Company delivered a total sale of ₹ 214 crores in the quarter ending March 31, 2021. While the quarter saw a decline of 4% vs last year, we will continue to ramp up to serve growing consumer demand backed by strong supply chain continuity plans.”
He further added, “Our top priority continues to be the health and safety of our employees and partners, while supporting communities through relief efforts under our ‘SEHAT’ (meaning Health) CSR initiative and through ‘P&G Suraksha India’ Covid-19 relief program. As P&G group, we have pledged to donate INR 50 Cr towards 10 lakh vaccine doses for 5 lakh citizens in partnership with state governments and local authorities.”